Subtype
Merkel Cell Carcinoma
CI-CAN-00006016MCCExplore in graph →
51 active trials3 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006016MCCExplore in graph →
Clinical trials
133 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (27)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03435640 | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies(REVEAL) | terminated | Phase 1 / Phase 2 | 64 | Nektar TherapeuticsINDUSTRY | 1 | Mar 8, 2023 | clinicaltrials |
| NCT05429866 | Immunological Variables Associated to ICI Toxicity in Cancer Patients | unknown | Phase 2 | 441 | Jules Bordet InstituteOTHER | 1 | Mar 8, 2023 | clinicaltrials |
| NCT03787602 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | unknown | Phase 1 / Phase 2 | 115 | Kartos Therapeutics, Inc.INDUSTRY | 10 | Mar 2, 2023 | clinicaltrials |
| NCT03545334 | Lymph Node Identification in Skin Malignancy Using ICG Transcutaneously Study(LIMIT) | completed | N/A | 93 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT01013779 | Merkel Positron Emission Tomography (PET) Protocol(MP3) | completed | Phase 2 | 43 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Nov 18, 2022 | clinicaltrials |
| NCT00540566 | Optical Biopsy of Human Skin in Conjunction With Laser Treatment | completed | — | 113 | University of California, IrvineOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | terminated | Phase 1 | 49 | Genocea Biosciences, Inc.INDUSTRY | 1 | Jul 15, 2022 | clinicaltrials |
| NCT02584829 | Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma | terminated | Phase 1 / Phase 2 | 8 | Fred Hutchinson Cancer CenterOTHER | 1 | Mar 22, 2022 | clinicaltrials |
| NCT03458117 | T-VEC in Non-melanoma Skin Cancer(20139157 T-VEC) | completed | Phase 1 | 26 | University of ZurichOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04874831 | Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) | withdrawn | Phase 2 | 0 | 4SC AGINDUSTRY | 0 | Nov 18, 2021 | clinicaltrials |
| NCT03652077 | A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies | completed | Phase 1 | 40 | Incyte CorporationINDUSTRY | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03988647 | Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma | terminated | Phase 2 | 1 | Stanford UniversityOTHER | 1 | Aug 9, 2021 | clinicaltrials |
| NCT02514824 | MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma | completed | Phase 1 / Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 29, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01913691 | Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Dec 17, 2019 | clinicaltrials |
| NCT03089658 | Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC) | approved for marketing | — | — | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 9, 2019 | clinicaltrials |
| NCT02035657 | A Proof-of-Concept Trial of GLA-SE in Patients With Merkel Cell Carcinoma | completed | Phase 1 | 10 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 13, 2018 | clinicaltrials |
| NCT02054884 | F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma | terminated | Phase 2 | 13 | Philogen S.p.A.INDUSTRY | 6 | May 18, 2018 | clinicaltrials |
| NCT02351128 | Treatment of Unresecable and/or Metastatic Merkel Cell Carcinoma by Somatostatine Analogues(PHRC-Merkel) | completed | Phase 2 | 35 | University Hospital, GrenobleOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT01758458 | Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT01204476 | Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma | completed | Phase 1 | 27 | National Cancer Institute (NCI)NIH | 1 | Jul 15, 2016 | clinicaltrials |
| NCT01155258 | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01526486 | Videoscopic Versus Open Inguinal Lymphadenectomy for Cancer | completed | N/A | 29 | Emory UniversityOTHER | 1 | May 6, 2015 | clinicaltrials |
| NCT00346385 | BB-10901 in Treating Patients With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 97 | ImmunoGen, Inc.INDUSTRY | 2 | Mar 26, 2015 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Jul 10, 2013 | clinicaltrials |
| NCT00004922 | Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 19, 2013 | clinicaltrials |
| NCT00079131 | Oblimersen in Treating Patients With Merkel Cell Carcinoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00068783 | S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00003549 | S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer | completed | Phase 2 | 80 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 8, 2012 | clinicaltrials |
| NCT00765193 | The Impact of Total Body Skin Examination on Skin Cancer Detection(TBSE) | completed | N/A | 14,381 | Medical University of GrazOTHER | 1 | Apr 15, 2010 | clinicaltrials |
Data updated 22 days agoSource updated Mar 8, 2023source: clinicaltrials